X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.61 USD
-0.03 (-4.86%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $0.64 +0.04 (5.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.61 USD
-0.03 (-4.86%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $0.64 +0.04 (5.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
by Zacks Equity Research
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
by Zacks Equity Research
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for December 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for December 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
X4 Pharmaceuticals (XFOR) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Arsanis Inc (XFOR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Arsanis Inc (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
X4 Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
X4 Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
X4 Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.